The United Kingdom and the United States have signed a landmark trade agreement that will keep zero duties on British medicine products entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on drugs through the National Health Service (NHS). This move secures that duties on these key exports will be held at zero for a timeframe of the next three years.
This development comes after previous warnings to hike tariffs on patented drug products, with potential rates mentioned as high as 100%.
"This deal between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," a release said.
Economic Impact
Pharmaceuticals represent one of the UK's most significant exports to the United States, which is easily the largest buyer for leading British pharmaceutical firms.
Statistics reveal that in the 12 months prior to the third quarter, the UK exported pharmaceutical products totaling £11.1bn to the US. This amount accounted for 17.4% of British export trade in that timeframe.
"This guarantee protects work, boosts investment and paves the way for the UK to establish itself as a global hub for medical research," a minister stated.
Key British Pledges
The deal involves several key pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must return to the NHS to control costs will be restricted at fifteen percent. In the past, repayments were more than twenty percent.
Industry Background
The deal comes amid a protracted dispute between the sector and the ministers over spending levels and approval rates.
The disagreement were heightened by assertions that American customers were paying significantly more for the same drugs than people in the other developed nations.
In recent months, several major drug company projects in the UK have been delayed or scrapped, while major funding commitments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to spend more on treatments, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
